April 6 11:30am - 4:00 PM
April 7 11:30am - 6:00 PM
April 8 11:30am - 4:00 PM
April 9 11:30am - 4:00 PM
The AAN Annual Meeting brings together thousands of neurologists and neuroscience professionals for the freshest lineup of top-tier education, the latest in scientific discoveries, and an abundance of opportunities to connect with friends and colleagues from around the world.
Take a look through our AAN 2025 poster presentations.
Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener in Adults With Focal Onset Seizures (FOS): Update From the Ongoing 7-year Open-Label Extension of X-TOLE
Jacqueline French, Roger Porter, Emilio Perucca, Martin Brodie, Cynthia Harden, Jenny Qian, Constanza Luzon Rosenblut, Christopher Kenney, Gregory N. Beatch
Is the Mental Health Burden of Epilepsy Under-Recognized in Patients Reporting Focal Onset Seizures? A Patient-Reported Outcomes Study
Joanne M. Wagner, Bhagyashree Oak, Brittany Smith, Amod Athavale, Jeffrey R. Skaar, Alvin Ong, Cynthia Harden
Efficacy of Azetukalner in Focal Onset Seizure (FOS) Subtypes: Results From the Double-Blind, Placebo Controlled X-TOLE Study
Emilio Perucca, Jacqueline French, Cynthia Harden, Jenny Qian, Constanza Luzon Rosenblut, Christopher Kenney, Gregory N. Beatch
Potassium channels play a major role in the control of neuronal excitability and represent a promising treatment target for epilepsy.7,8
K+ channels repolarize membranes to end the action potential9
Kv7 channels9
View our clinical trial brochure for azetukalner in focal onset seizures and primary generalized tonic-clonic seizures to learn more.
VIEW BROCHUREX‑TOLE2 and X‑TOLE3 are two identical Phase 3, multicenter, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy, safety, and tolerability of azetukalner as adjunctive treatment in adults aged ≥18 years diagnosed with FOS who are taking 1 to 3 ASMs.
Approximately 360 eligible subjects will be randomized 1:1:1 (azetukalner
ASM, antiseizure medication; FOS, focal onset seizures.
Screening/baseline period: Up to 9.5 weeks duration to assess the frequency of seizures.
Double-blind period (DBP): 12 weeks duration. There is no titration period.
Follow-up period: 8 weeks duration after the last dose of study drug for subjects who do not complete the 12-week DBP or who complete the DBP but do not enter the OLE study.
On completion of the double-blind period in X‑TOLE2 or X‑TOLE3, eligible patients may enter an open-label extension study for up to three years.13
Primary efficacy endpoint
Median percent change in monthly focal seizure frequency from baseline to DBP of azetukalner compared to placebo.1,2
For additional information, including inclusion and exclusion criteria, visit the X‑TOLE2 and X‑TOLE3 clinical trial pages.
X-ACKT is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of azetukalner as adjunctive treatment in adults aged ≥12 years with a seizure frequency of ≥3 PGTCS during the last 8 weeks of the baseline period and taking 1 to 3 ASMs.
Approximately 160 eligible subjects will be randomly assigned 1:1 (azetukalner
ASM, antiseizure medication; PGTCS, primary generalized tonic-clonic seizures.
Screening/baseline period: Up to 9.5 weeks duration to assess the frequency of seizures.
Double-blind period (DBP): 12 weeks duration. There is no titration period.
Follow-up period: 8 weeks duration after the last dose of study drug for subjects who do not complete the 12-week DBP or who complete the DBP but do not enter the OLE study.
On completion of the double-blind period in X-ACKT, eligible patients may enter an open-label extension study for up to three years.13
Primary efficacy endpoint
Median percent change in monthly PGTCS frequency from baseline through the DBP of azetukalner versus placebo.3
For additional information, including inclusion and exclusion criteria, visit the
Find out more about our azetukalner Epilepsy Phase 3 program by contacting medicalaffairs@xenon-pharma.com.